67 results about "Diabetic patient" patented technology

The utility model relates to nursing instrument technical field, and disclose a kind of diabetic foot protection device, including protection device bottom pad, the top of protection device bottom pad is equipped with flexible protection body, the side of protection device bottom pad is equipped with rotating shaft, the side of rotating shaft is rotatably connected with hard protection body, the side of protection device bottom pad is fixedly connected with first connecting block, the side of hard protection body is fixedly connected with connecting plate, the top of first connecting block is equipped with the insertion slot, the top of connecting plate is fixedly connected with second connecting block, the one end of second connecting block is equipped with structure slot.The foot protection device for lower limb nursing of diabetic patient can make medical staff more conveniently observe and replace the wound dressing of affected side toe, help to prevent disease from getting worse, and improve the efficiency of nursing work, at the same time, it reduces the discomfort of patient suffered from repeatedly wearing protection device.

Provided herein are pharmaceutical formulations comprising glucokinase activator, or a prodrug, or a pharmaceutically acceptable salt, an isotope labeled analogue, a crystalline form, a hydrate, a solvate, or a diastereomeric or enantiomeric form thereof and the use thereof for treating diseases; the pharmaceutical formulations are in the form of immediate-release formulations, extended-release formulations, or combination of immediate-release formulation and extended-release formulations. The pharmaceutical formulations achieved once-a-day therapy for some diseases, in particular, type II Diabetes Mellitus with obesity. The pharmaceutical formulations exhibit sustained 24 hours of glucose-lowering effects. The pharmaceutical formulations also achieved lower Cmax, extended T1 / 2 as well as maintained similar bioavailability and increased MRT compared with commercial Dorzagliatin tablet, enhanced the pharmacology effect of restoring the glucose stimulated GLP-1 secretion in diabetes with obesity.

This invention discloses a method for preparing low-GI fruit and vegetable crisps, belonging to the field of fruit and vegetable deep processing technology. Through innovative design of color-protecting liquid and impregnation liquid, this invention enables the prepared fruit and vegetable crisps to possess both low-GI properties and excellent antioxidant capacity, precisely meeting the consumption needs of specific groups such as diabetic patients and those trying to lose weight. Therefore, it has significant importance and market application value in the field of fruit and vegetable deep processing technology.

1. Name of the product in this design: Graphical User Interface for Launching Applications on an Electronic Device. 2. Purpose of this design: An electronic device. 3. The key design features of this product are its icon-based graphical user interface. 4. Images or photographs that best illustrate the design's key points: enlarged details. 5. Uses of graphical user interfaces: Iconic graphical user interfaces are used for human-computer interaction and to enable the functions of electronic devices. They can also be used to launch applications, such as applications that provide dietary advice to diabetic patients. 6. Human-computer interaction method of graphical user interface: The graphical user interface can be interacted with by clicking the icon to launch the application.

A method of providing personalized treatment for a diabetes patient including a remote device which is configured to receive a first data indicative of an analyte level of a subject during a first time period, retrieve a first glycated hemoglobin level for the subject associated with the first time period, calculate a first personal apparent glycation ratio for the first time period using the received first data and the retrieved first glycated hemoglobin level, compare the calculated first personal apparent glycation ratio to a representative apparent glycation ratio, generate a recommendation based on the comparison, and display a graphical interface comprising the calculated first personal apparent glycation ratio, the representative apparent glycation ratio, and the comparison.

The present invention relates to a test kit for performing an assay to detect and measure at least one autoantibody molecule in a subject developing type 1 diabetes (T1D). The invention more specifically relates to a recombinant antigen molecule fused to a bioluminescent reporter protein to detect an autoantibody molecule against a self-antigen. Said self-antigen is preferably expressed by pancreatic islet beta cells and include insulin, proinsulin, Glutamate decarboxylase 65, islet antigen 2, and Zinc transporter 8. More specifically, the present invention relates to an assay comprising a set of at least three recombinant antigen molecules in a single composition, the antigen molecules being selected from the list comprising recombinant human Glutamate decarboxylase 65, recombinant human islet antigen 2, recombinant human Zinc transporter 8, recombinant human insulin, and recombinant human proinsulin. The invention further relates to methods for determining the presence and / or level of at least one autoantibody molecule in a sample from a human subject developing T1D using said recombinant antigen molecules. According to the invention, the presence, absence, or amount of one or more autoantibody molecules against said self-antigens is determined with a luciferase immune precipitation system (LIPS) assay or a modified version of a LIPS assay, i.e., a solid phase capture LIPS (scLIPS) assay.

The application discloses a diabetes patient biological age calculation method based on glycosylation markers and a multi-task deep learning framework, and belongs to the technical field of bioinformatics and medical data processing technology, and the method comprises the following steps: obtaining glycomics feature data and clinical examination data of diabetes patients; preprocessing the data; obtaining a feature set by adopting a multi-method screening and fusion strategy; constructing a deep learning model comprising a multi-modal feature fusion module and a multi-task learning module for training, wherein the multi-task learning module comprises a main task of aging clock regression and at least one auxiliary task; and outputting biological age prediction values and age acceleration evaluation results of individuals by using the trained model. The method realizes deep fusion of multi-modal biological data and exclusive modeling for the diabetes population, can accurately quantify the biological aging process and the deviation degree relative to the calendar age, and provides an objective quantitative tool for clinical evaluation.

This invention relates to the field of urine glucose monitoring technology, and more particularly to a method and system for monitoring urine glucose data from adult diapers. The method first interacts with a nursing management system to obtain daily care milestones for the patient, and connects to a wearable terminal to generate a visual monitoring interface. Secondly, at preset milestones, multiple sensors integrated into the inner layer of the diaper collect data, combining health parameters to identify abnormalities and predict the level of blood glucose abnormalities. Subsequently, based on historical data from multiple milestones, a blood glucose fluctuation trend curve is generated on the interface. Finally, a personalized intervention plan is formulated based on the abnormality level and the trend curve, implementing targeted nursing care. This invention achieves non-invasive continuous monitoring through multi-source signal fusion to combat interference; it possesses the ability to predict blood glucose trends, transforming passive alarms into proactive prevention; and through a visual interface and intelligent decision-making closed loop, it significantly improves the accuracy, efficiency, and comfort of nursing care for diabetic patients.

This invention discloses a method and device for segmenting diabetic retinopathy based on feature interaction, comprising: constructing a feature interaction module for semantic relationship modeling of multiple lesions, embedding it into each ViT block encoding layer of the image encoder of the image segmentation model SAM, obtaining an image segmentation model FIASAM fused with the feature interaction module; training the image segmentation model FIASAM fused with the feature interaction module using fundus color image-mask annotation; acquiring fundus color images of diabetic patients, inputting them into the trained image segmentation model FIASAM fused with the feature interaction module, and generating image segmentation results containing all lesion types. This invention can enhance the feature interaction capabilities between different lesion types of diabetic retinopathy and between lesions and the background of fundus color images, thereby improving the accuracy and reliability of automatic segmentation of multiple lesions in fundus color images.

The application discloses a composition containing burdock polysaccharide for reducing blood sugar of type 2 diabetes patients and a preparation method and application thereof, and belongs to the technical field of medicine and food. The composition contains burdock polysaccharide, chitooligosaccharide, chlorogenic acid, epicatechin, resveratrol, ginsenoside Rd, and vitamin D, vitamin B1, vitamin B6, vitamin B12, magnesium glycinate and thaumatin protein. The application takes burdock polysaccharide as a core long-acting component, takes chitooligosaccharide as a short-acting synergistic component, constructs a long-short-acting synergistic blood sugar reducing system, and realizes the organic combination of rapid blood sugar reduction and stable blood sugar control. Experiments show that the composition can significantly reduce the fasting blood sugar of type 2 diabetes model rats, improve insulin resistance and glucose tolerance, reduce blood lipid and inflammatory factor levels, and reduce oxidative stress damage. The alpha-glucosidase inhibitory activity and in-vivo comprehensive blood sugar reducing effect of the composition are better than those of single burdock polysaccharide, and the composition has good taste and is suitable for long-term use of diabetes patients.

Disclosed herein is a healthcare management system and method utilizing machine learning based predictive analytics to improve patient adherence rates for chronic care management (e.g., diabetes). An example system may include a computing device configured to establish a customer analytical record to synthetize over a plurality of selected attributes to form a patient centric view of patient behaviors, attitude, characteristics based upon data related to chronic disease state management and social determinants of health, consumer experience to determine, using a predictive artificial intelligence model, a patient's predictive adherence for next 1-3 months, and determine tailored intervention plans to engage patients for continuing adherence.

The application relates to the field of medical health data processing, and specifically provides a personalized insulin dose recommendation method and device for a diabetes patient, which has the following steps: S1, multi-source data preprocessing: collecting real-time dynamic data and static personalized parameters of the patient, performing outlier elimination, missing value completion, timestamp alignment and feature standardization processing on the data, and generating a time sequence matrix for input of an adaptive model; S2, constructing and training an LSTM-GRU blood glucose prediction model; S3, constructing and training a reinforcement learning dose decision model; and S4, closed-loop optimization and dose recommendation. Compared with the prior art, the application can significantly improve the accuracy and personalization degree of insulin dose recommendation, and provides reliable technical support for precise blood glucose management of the diabetes patient.

This application relates to the field of blood glucose detection technology, and in particular to a non-invasive / minimally invasive blood glucose prediction system, method, and storage medium. The system includes a data acquisition module for acquiring blood glucose and physiological parameters non-invasively and minimally invasively, and inputting them into a blood glucose detection model; and a blood glucose prediction module for outputting predicted blood glucose values ​​through the blood glucose detection model. This application overcomes the limitation of conventional blood glucose detection models that rely solely on single real-time data by deeply integrating blood glucose and physiological parameters. Physiological parameters reflect the impact of real-time physiological state on blood glucose; blood glucose parameters reflect the current trend of blood glucose changes; and the blood glucose detection model establishes a correlation mechanism for blood glucose changes, facilitating patient self-management and remote monitoring by medical staff, providing reliable assurance for the long-term management of diabetic patients.

The application discloses a prediction model of the risk of atherosclerosis of a type 2 diabetes patient and a construction method thereof, and the construction method comprises the following steps: obtaining general information, serum biochemical indexes and a brachial-ankle pulse wave velocity of the type 2 diabetes patient; calculating a ratio of visceral fat area and subcutaneous fat area of the patient; comparing the correlation of the general information and the serum biochemical indexes by using a single factor variance and a chi-square test method to obtain variables with statistical differences; determining influencing factors of the type 2 diabetes patient combined with atherosclerosis by using Spearman correlation analysis and multivariate logistic regression analysis; and constructing a logistic regression model: Logit (H) =-4.647+1.013*V / S+0.099*age-0.527*smoking+0.67*Hypertension-0.007*Cr, namely, the prediction model. The prediction model has good prediction performance and high clinical application value.

This invention belongs to the field of artificial intelligence technology. It discloses a risk prediction system for diabetic complications based on graph neural networks and knowledge graphs. The system includes a physiological feature perception module, which collects physiological perception data from diabetic patients, performs time synchronization and normalization on the data, and separates stable and perturbation feature components; a pathological potential mapping module, which, based on the semantic structure of the knowledge graph, maps stable feature components to basic physiological nodes and perturbation feature components to potential pathological activation nodes, introduces a pathological potential function, and establishes a pathological potential mapping network; and a pathological activation identification module, which calculates the potential pathological energy of each potential pathological activation node in the pathological potential mapping network using a graph neural network. When the potential pathological energy exceeds a preset potential pathological energy threshold, it is marked as a pathological activation source node; thus achieving early warning of diabetic complications.

This invention discloses an optimization method and system for a predictive model of diabetic complications. It involves collecting routine laboratory test data from diabetic patients, performing preprocessing such as missing value removal, label merging, and SMOTE resampling to construct a balanced dataset. The average importance of indicators is evaluated using multiple machine learning models to select a subset of key features. Random forest, XGBoost, support vector machine, and multilayer perceptron are selected as base classifiers, and after hyperparameter optimization, a stacked ensemble learning model is constructed to further improve predictive performance. Finally, the model is packaged as an API service and embedded into a hospital information system to achieve high-precision, low-cost, and real-time risk prediction of diabetic complications. Experimental results show that this invention achieves an accuracy of 98.5% and an AUC of 99.76% in predicting diabetic nephropathy complications, outperforming single models.

This invention discloses a composite scaffold for promoting bone regeneration in diabetic patients, its preparation method, and its applications, relating to the field of medical biomaterials technology. The composite scaffold for promoting bone regeneration in diabetic patients comprises: a three-dimensional porous framework; and a bioactive hydrogel layer loaded with naringin. The bioactive hydrogel layer loaded with naringin is coated on the surface and pore walls of the three-dimensional porous framework. The technical solution provided by this invention uses a 3D-printed PLGA / HA porous framework to provide mechanical support and osteoconductivity, and a supramolecular hydrogel coating loaded with naringin to endow it with immunomodulatory and drug sustained-release functions. This scaffold has good hydrophilicity and biocompatibility, and can effectively induce macrophage polarization towards the M2 anti-inflammatory phenotype by activating the JAK-STAT signaling pathway, improving the local inflammatory microenvironment of diabetic bone defects. Simultaneously, it indirectly promotes vascular endothelial cell migration, lumen formation, and osteogenic differentiation of bone marrow mesenchymal stem cells by regulating macrophages.

The present invention describes the preparation of flour and protein based on argan cake for food use as well as its bitterness reduction, with a high content of vegetable proteins, using only argan seeds or cakes as raw material and without adding any chemical product that may alter its composition, all that allows it, obtain flour without sugar and gluten. A flour suitable for diabetics and with a protein content greater than 50 percent.,

This invention relates to a low-GI nutritionally regulated gel-type swallowing aid product and its preparation method. The gel-type swallowing aid product comprises a low-GI gel matrix, popping beads, and a complex additive. The low-GI gel matrix is ​​prepared from konjac flour, resistant starch, erythritol, oat fiber, a complex prebiotic, and water. The popping beads consist of an outer shell and a prebiotic filling encapsulated within the outer shell. The prebiotic filling comprises probiotic powder, chitosan oligosaccharide, chitin oligosaccharide, vitamin complex, trace elements, anthocyanins, and MCT oil. Compared with existing technologies, this invention, based on the use of low-GI ingredients and combined with popping beads containing a prebiotic filling, enhances the patient's chewing and swallowing ability, improves the product's nutritional value, and provides a novel nutritional functional gel option for swallowing aids for diabetic patients and those with swallowing difficulties.

The application discloses a traditional Chinese medicine composition, preparation and application for treating type 2 diabetes and / or promoting remission of metabolic syndrome mainly caused by abnormal blood sugar. The composition comprises Fushen, Huanglian, Shengshigao, Tianhuafen, Zhimu, Fangji and Gegen, and selectively contains Shengjiang. The composition can reduce the fasting blood sugar, 2h postprandial blood sugar and glycosylated hemoglobin level of a type 2 diabetes patient, improve insulin resistance and promote physiological secretion of insulin, thereby being used for treating type 2 diabetes and promoting remission of type 2 diabetes. Meanwhile, the composition can comprehensively reduce blood pressure, regulate blood fat, reduce body weight and waist circumference and comprehensively correct metabolic syndrome; the composition has no obvious liver and kidney toxicity and has a liver function protection effect, and therefore has high safety.

The application discloses a kind of comprehensive microcirculation diabetes condition assessment system and method based on multi-modal parameters, belong to medical detection technical field.The system includes: multi-modal data integration acquisition module, for synchronous acquisition nail fold microcirculation video image of the finger and the toe of diabetic patient, blood oxygen saturation data and temperature, humidity data;Data processing and analysis module is used to process the microcirculation video image, extracts microvessel morphology and dynamics parameters, and is fused with blood oxygen saturation, temperature, humidity data, forms multi-modal feature vector;And condition assessment module is used to input the multi-modal feature vector to pre-trained condition assessment model, and outputs comprehensive assessment report about user diabetes microcirculation disorder grade, condition progression risk and complication tendency.The application is through non-invasive, synchronous comparison finger and toe multidimensional physiological parameters, solves the single problem that diabetes extremity distal microcirculation detection lags behind in the prior art, realizes early, dynamic and accurate assessment to diabetes condition.

This invention discloses a type 1 diabetes vaccine based on autoantigen polypeptide molecules. The invention provides a series of immunogenic autoantigens as active ingredients in type 1 diabetes vaccines. This invention utilizes computer-simulated amino acid mutations of type 1 diabetes autoantigen sequences obtained from type 1 diabetes patients, supplemented by rational design based on the HLA-peptide-TCR ternary complex structure; targeted optimization enhances the binding affinity between the antigen and immune molecules, thereby achieving significant proliferation of type 1 diabetes-related CD4+ T lymphocytes. The autoantigens of this invention will serve as the basis for the development of type 1 diabetes vaccines in the form of artificially synthesized polypeptide molecules.

The application provides a sugar alcohol solvent and its application in preparation of a product containing ginkgo leaf extract, and belongs to the technical field of food and health care products. The sugar alcohol solvent comprises xylitol, and the mass percentage of xylitol in the sugar alcohol solvent is 30-50%. The sugar alcohol solvent is safe and non-toxic, has simple preparation process and low cost, can be used as a solubilizing solvent for the ginkgo leaf extract, can improve the solubility of the ginkgo leaf extract without affecting the stability and biological activity of ginkgolides and ginkgo flavones in the ginkgo leaf extract, can be used as an intermediate purification solvent for preparation of ginkgolide monomers, is safe and non-toxic, and can be used as a new solvent for the ginkgo leaf extract to prepare a liquid oral ginkgo leaf extract, so that liquid health care is realized, and safe drug delivery is realized for diagnosis and treatment of cardiovascular and cerebrovascular diseases of special groups (such as diabetic patients).

The application discloses a kind of based on multi-modal fusion's diabetic retinopathy auxiliary diagnosis method, comprising the following steps: S1, the fundus image of patient is preprocessed operation;S2, the text information of patient is preprocessed operation;S3, the feature extraction operation is carried out to the fundus image after preprocessing, and image feature vector is obtained;S4, the feature extraction operation is carried out to the text information after preprocessing, and text semantic vector is obtained;S5, image feature vector, text semantic vector are combined with medical mask gate and carry out high-order sparse tensor fusion, and obtain the feature vector after fusion and diagnostic category prediction probability;S6, the diagnosis result is combined with bidirectional back-propagation mechanism and carries out graph-text joint tracing, and outputs diagnosis heat map and its corresponding dynamic linkage explanation.The application can provide fast diagnosis suggestion for doctors, reduce artificial reading film pressure, reduce misdiagnosis false negative rate, accelerate the retinal screening efficiency of diabetic patient.

This invention relates to the field of functional beverage technology, specifically to a functional beverage containing willowherb water extract, its preparation method, and its application. The beverage comprises the following components in the indicated mass-volume ratios: willowherb water extract dry extract 0.6-1.8 g / 30 mL, fructooligosaccharides 1.2-3.6 g / 30 mL, citric acid 0.06-0.18 g / 30 mL, xanthan gum 0.036-0.084 g / 30 mL, and L-ascorbic acid 0.03-0.15 g / 30 mL. While ensuring excellent color, flavor, and taste, the beverage achieves low sugar content, suitable acidity, and good stability, making it suitable for a wide range of consumers, including those with diabetes. The beverage preparation process is simple and reproducible, facilitating standardized production and large-scale promotion. It provides a feasible path for the high-value development of willowherb resources. Fructooligosaccharides hardly participate in sugar metabolism and do not raise blood sugar. The combination of willowherb's sleep-aiding function and low sugar content makes it suitable as a nighttime beverage for diabetic patients.

The application discloses a kind of auxiliary detection devices for treating diabetic patients, it is related to diabetes detection technical field, including blood sampling pen and blood glucose meter, still including fixed block, the fixed block is fixed between the blood sampling pen and blood glucose meter, for connecting two, the blood sampling pen and blood glucose meter outside cover with cover shell, the cover shell one side is open, and the other side is provided with through-hole.The beneficial effects of the present application are: by the setting of auxiliary assembly, blood sampling pen and blood glucose meter are combined together, in the detection process, the steps of puncture and blood sampling can be completed without interval, multiple steps of hand operation is saved, blood sample exposure time is shortened, blood coagulation, oxidation, dripping or pollution is avoided, blood sample purity is guaranteed, detection accuracy is improved, and operation process is greatly simplified, single hand can be completed, reduce the use difficulty of old people, people with poor eyesight and patients with difficulty in movement, improve monitoring compliance and safety.

This invention discloses the application of adenosine deaminase or its modified forms in the preparation of therapeutic drugs that improve pancreatic islet inflammation and protect pancreatic β-cell function in diabetic patients. This invention is the first to discover that exogenous ADA, through a systemic clearance-local decompression mechanism, enhances circulating ADO clearance, reduces tissue ADO load, restores compensatoryly elevated tissue ADA activity to normal, significantly reduces macrophage infiltration in the islets, inhibits inflammatory factor expression, promotes β-cell proliferation and functional recovery, and improves glucose and lipid metabolism. This invention provides a disease-modifying therapy for diabetes that can simultaneously regulate immunity and metabolism, possessing extremely high clinical application value.

The application discloses a rehabilitation management method and system for a diabetic patient, relates to the technical field of diabetic patient management, and generates a comprehensive state parameter set by monitoring the blood sugar condition of the patient in real time and acquiring the currently taken medicine, identity information and other medical history; compares the blood sugar data in the comprehensive state parameter set with a preset safety threshold range, generates a preliminary rehabilitation recommendation scheme according to the comparison result and the current time node; predicts the time for the blood sugar of the patient to return to normal after the patient executes the preliminary rehabilitation recommendation scheme through a prediction model and obtains a predicted blood sugar change curve, and then calculates the difference between the time for the blood sugar of the patient to actually return to normal after the patient executes the preliminary rehabilitation recommendation scheme; and based on the difference and the rehabilitation condition and the blood sugar fluctuation condition of the patient in the previous period, the rehabilitation recommendation scheme generated next time is fine-tuned, so that the patient can perform scientific rehabilitation treatment without the instruction of medical staff.

A method for predicting cardiovascular disease in diabetic patients and a system therefor are provided. A method for predicting cardiovascular disease according to some embodiments may comprise the steps of: obtaining one or more machine-learning models prepared to predict risk information related to cardiovascular disease in diabetic patients; obtaining state information of a target diabetic patient; and predicting risk information of the target diabetic patient related to cardiovascular disease by inputting the obtained state information into the one or more machine-learning models. According to the method, the risk of developing cardiovascular disease among various complications that can develop in diabetic patients can be accurately predicted at an early stage.